Obermatt
See Similar Stocks →

Cytek Biosciences

NSQ:CTKB · US23285D1090
Life Sciences Tools & ServicesSmall

360

38
Profit price62
Owner Earnings Yield1
Dividend Yield1
Price/Sales62
EV / Gross Profit91
Price/Book67
Return on Capital34
Cash Return on Capital29
Return on Equity38
EBIT Margin28
Gross Profitability70
Accruals57
Owner Earnings Margin24
Sales growth41
Profit growth52
Reinvestment90
Price momentum61
Debt load87
Refinancing75
Debt Payback1
Liquidity12
Analyst ratings23
Opinion Changes50
Price Target Upside70
Market mood68
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cytek Biosciences doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2014
Employees375
Websitecytekbio.com
ISINUS23285D1090
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsImage RecognitionProcess AutomationBiomedical EngineeringImmunologySensorsArtificial IntelligenceDetectors, Sensors and MemsSoftware DevelopmentComputer VisionOncologyBiotechnologyHealth CareManufacturingScience and Engineering

Description

Cytek Biosciences, Inc. operates as a cell analysis solutions company advancing the next generation of research and clinical tools with the company’s novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple la…

Analysis

Middle-of-the-road

Cytek Biosciences, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 2/20 on our value-creation score: not creating value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
61
2023202420252026

All-time high

87

Jan 2025

All-time low

30

Jan 2024

Average rank

60

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
62
46
25
13
Price/Earnings
1
1
1
1
Price/Book
67
65
39
43
Dividend Yield
1
1
1
1
Value (overall)
23
47
1
5

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cytek Biosciences with its peers
Revvity
NYQ:RVTY
52
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Mesa Laboratories
NSQ:MLAB
69
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Quanterix
NMQ:QTRX
43
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Bio-Techne
NSQ:TECH
74
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Inotiv
NAQ:NOTV
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Pacific Biosciences of California
NSQ:PACB
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →